Achieve Life Sciences, Inc.
ACHV
$7.63
-$0.22-2.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 103.37% | -33.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 75.78% | -28.97% | |||
| Operating Income | -75.78% | 28.97% | |||
| Income Before Tax | -635.34% | 30.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -635.34% | 30.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -635.34% | 30.65% | |||
| EBIT | -75.78% | 28.97% | |||
| EBITDA | -76.20% | 29.09% | |||
| EPS Basic | -319.74% | 30.78% | |||
| Normalized Basic EPS | -307.76% | 28.30% | |||
| EPS Diluted | -319.74% | 30.78% | |||
| Normalized Diluted EPS | -307.76% | 28.30% | |||
| Average Basic Shares Outstanding | 75.17% | 0.20% | |||
| Average Diluted Shares Outstanding | 75.17% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||